Advertisement

PharmacoEconomics & Outcomes News

, Volume 820, Issue 1, pp 13–13 | Cite as

Dulaglutide cost effective as third-line therapy in T2DM in Canada

Clinical study
  • 6 Downloads

Reference

  1. Pollock RF, et al. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. Journal of Comparative Effectiveness Research : 15 Jan 2019. Available from: URL: https://doi.org/10.2217/cer-2018-0073

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations